DE60121811D1 - Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür - Google Patents

Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür

Info

Publication number
DE60121811D1
DE60121811D1 DE60121811T DE60121811T DE60121811D1 DE 60121811 D1 DE60121811 D1 DE 60121811D1 DE 60121811 T DE60121811 T DE 60121811T DE 60121811 T DE60121811 T DE 60121811T DE 60121811 D1 DE60121811 D1 DE 60121811D1
Authority
DE
Germany
Prior art keywords
tirc7
liganden
binding
alpha
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121811T
Other languages
English (en)
Other versions
DE60121811T2 (de
Inventor
Nalan Utku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellact Pharma 44227 Dortmund De GmbH
Original Assignee
GENPAT77 PHARMACOGENETICS AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENPAT77 PHARMACOGENETICS AG filed Critical GENPAT77 PHARMACOGENETICS AG
Publication of DE60121811D1 publication Critical patent/DE60121811D1/de
Application granted granted Critical
Publication of DE60121811T2 publication Critical patent/DE60121811T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60121811T 2000-10-30 2001-10-29 Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür Expired - Lifetime DE60121811T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00123666 2000-10-30
EP00123666 2000-10-30
PCT/EP2001/012485 WO2002036149A2 (en) 2000-10-30 2001-10-29 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof

Publications (2)

Publication Number Publication Date
DE60121811D1 true DE60121811D1 (de) 2006-09-07
DE60121811T2 DE60121811T2 (de) 2007-01-18

Family

ID=8170238

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121811T Expired - Lifetime DE60121811T2 (de) 2000-10-30 2001-10-29 Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür

Country Status (9)

Country Link
US (1) US20040072780A1 (de)
EP (1) EP1353687B1 (de)
JP (1) JP2004512371A (de)
AT (1) ATE333889T1 (de)
AU (2) AU2177502A (de)
CA (1) CA2425583A1 (de)
DE (1) DE60121811T2 (de)
ES (1) ES2269505T3 (de)
WO (1) WO2002036149A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486924A1 (en) * 2001-11-27 2003-06-05 Nalan Utku Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
EP1492818B1 (de) * 2001-12-21 2012-08-08 CellAct Pharma GmbH Anti-tirc7 antikörper und tnf-alpha antagonisten zur kombinationstherapie von inflammatorischen erkrankungen
WO2022226054A2 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DE69820449T2 (de) * 1997-08-29 2005-03-10 The Brigham And Women's Hospital Inc., Boston T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
US20050048067A1 (en) * 2001-09-17 2005-03-03 Nalan Utku Peptides capable of modulating immune response

Also Published As

Publication number Publication date
ES2269505T3 (es) 2007-04-01
CA2425583A1 (en) 2002-05-10
WO2002036149A2 (en) 2002-05-10
JP2004512371A (ja) 2004-04-22
EP1353687B1 (de) 2006-07-26
EP1353687A2 (de) 2003-10-22
DE60121811T2 (de) 2007-01-18
WO2002036149A3 (en) 2003-08-28
AU2177502A (en) 2002-05-15
US20040072780A1 (en) 2004-04-15
AU2002221775B2 (en) 2006-11-23
ATE333889T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATA1302001A (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
ATE319825T1 (de) Verfahren und zusammensetzungen zur immunomodulation
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE602004030541D1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE356147T1 (de) Antikörper zur vorbeugung und behandlung von e. coli aeec krankheiten
DE60121811D1 (de) Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
EP2322209A3 (de) Tumorspezifische Oligosaccharid-Epitope und deren Verwendung
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CELLACT PHARMA GMBH, 44227 DORTMUND, DE